Given both STAT3 and p53 are effective targets and the presence of opposing STAT3 − p53 regulatory loops, co-targeting STAT3 and p53 by Prohep was therefore suggested to be promising in CRC regulation. The gene discussed is TP53; the disease is colorectal carcinoma.